20271 Goldenrod Lane
4 articles with Neuraly Inc
CORRECTING and REPLACING Neuraly Announces First Patient Dosed in Phase 2 Clinical Trial of NLY01 for Patients with Parkinson’s Disease
Novel Mechanism of Action Inhibits Pathological Activation of Microglial Cells and Prevents Neuronal Cell Death
D&D Pharmatech Raises $137.1M in Series B Financing to Advance Potential Disease-Modifying Treatments
D&D Pharmatech Inc., a clinical-stage biotechnology company focused on development and commercialization of revolutionary medicines, and parent company of U.S.-based Neuraly Inc., Precision Molecular, Inc. and Theraly Fibrosis Inc., announced that it has completed a $137.1 million Series B round of financing from U.S. and Korean investors.
Startup Neuraly Raises $36M to Bring Potential Disease-Modifying Treatments to Patients with Parkinson’s Disease
Research published in Nature Medicine demonstrates protection against dopamine loss and behavioral deficits associated with Parkinson’s disease
Maryland-based Neuraly surged forth from the startup gate with $36 million in Series A funding that will finance the company’s research into the development of therapies for neurodegenerative disorders.